← All patents

US20220370600A1

Multigenic mva-sars-cov-2 vaccine

University of Texas System

Abstract

The present invention includes compositions and methods of making and using an immunogenic protein for mucosal delivery comprising at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid identity to a multigenic coronavirus vaccine on a modified vaccinia ankara (MVA) vector …

University
University of Texas System
Assignee
Board Of Regents, The University Of Texas System
Inventor
Haitao Hu
Priority date
May 21, 2021
Filing date
May 18, 2022
Publication date
November 24, 2022
Language
en
Metadata fetched
August 29, 2026 00:30